Corporate Governance

Mr. Roman Kyrychynskyi, aged 50, was appointed as our independent non-executive Director in June 2023 with effect from the Listing Date.

He began his career at AMD in 2000 as Group Manager for Planning and Pricing, later serving as Financial Controller (2007-2009). He advanced to Product Director in 2009, Senior Director in 2018, and Vice President in 2021, overseeing inventory, revenue management, product valuations, and the memory BU P&L. Since 2007, he has also managed AMD’s global memory procurement, a vital function supporting the company’s growth.

Mr. Kyrychynskyi is a member of the Chartered Professional Accountants of Canada. He earned his Bachelor of Commerce (Honours) degree from Queen’s University in Canada in May 2000.

Ms. Denitsa Milanova, Ph.D., aged 41, was appointed as our independent non-executive Director in June 2023 with effect from the Listing Date.

Ms. Milanova is a founder and chief executive officer of Medici Therapeutics, Inc., an immuno-oncology company based in Boston, San Francisco and Emeryville, since October 2022. Prior to founding Medici, Ms. Milanova served as a Technology Development Fellow and Principal Investigator at Wyss Institute for Biologically Inspired Engineering of Harvard University from April 2018 to October 2022, and as a Postdoctoral Fellow in the Genetics Department of Harvard Medical School working with Prof. George Church from December 2015 to April 2018. Ms. Milanova also served as a business consultant at Ohana Biosciences (a subsidiary of Flagship Pioneering), a Boston-based life science company incubator, from April 2016 to November 2017.

Ms. Milanova became a Doctoral Fellow of the Stanford Microfluidics Laboratory under Prof. Juan Santiago at Stanford University School of Engineering in August 2008. In 2010, Ms. Milanova continued her degree while also collaborating with Profs. Annelise Barron in Molecular Bioengineering for Medicine and Biotechnology and Michael Snyder at Stanford University School of Medicine from January 2015 to January 2016. Prior to that, Ms. Milanova served as an undergraduate researcher at the Nanofluids and Two-Phase Flow Laboratory during her studies at University of Central Florida.

Ms. Milanova received her B.S. in Mechanical Engineering at University of Central Florida in the United States in May 2008. Ms. Milanova received her M.Sc. in Mechanical Engineering in June 2010, her M.Sc. in Management Science and Engineering (an executive business degree with a focus on entrepreneurship) in June 2013, and her Ph.D. in Mechanical Engineering in January 2016, all from Stanford University in the United States. During her studies, Ms. Milanova was awarded a Stanford Graduate School of Engineering Fellowship in 2008, and a Stanford Bio-X Medtronic Fellowship in 2011, both of which provided outstanding young researchers with full financial support.

Mr. Jingsong Wang, Ph.D. (王勁松), aged 61, was appointed as our independent non-executive Director in June 2023 with effect from the Listing Date.

Mr. Wang has served as an executive director, the chief executive officer and chairman of the board of HBM Holdings Limited, a company listed on the Hong Kong Stock Exchange (HKEx: 2142), since July 2016. Mr. Wang is the principal founder of HBM Holdings Limited. From November 2011 to December 2015, Mr. Wang served as the head of China research and development at Sanofi.

Mr. Wang has served as an independent non-executive director of Frontage Holdings Corporation, a company listed on the Hong Kong Stock Exchange (HKEx: 1521), since April 2018. Previously, he was an independent non-executive director of Xinjiang Bai Hua Cun Pharma Tech Co., Ltd. (新疆百花村醫藥集團股份有限公司), a company listed on the Shanghai Stock Exchange (SSE: 600721), from September 2021 to August 2024.

Mr. Wang received his M.D. in clinical medicine from Xuzhou Medical College in China in June 1986, his master’s degree in medical science (immunology) from Jilin University (formerly known as Norman Bethune University of Medical Science before the combination with Jilin University) in China in July 1989, and his Ph.D. in molecular pharmacology from China Pharmaceutical University in China in July 2011. 

Mr. Wang also obtained a physician qualification awarded by the Commonwealth of Massachusetts Board of Registration in Medicine in May 2002, as well as a Diplomate in Internal Medicine and a Diplomate in Rheumatology, both awarded by the American Board of Internal Medicine in 2003 and 2004 respectively. He obtained Medical Physician and Surgeon certificate from the State Board of Medicine of the Commonwealth of Pennsylvania in 2006. From June 2001 to June 2005, Mr.Wang served as a research/clinical fellow in rheumatology at Brigham and Women’s Hospital and Harvard Medical School.